摘要
目的观察老年肺结核患者采用利福喷丁胶囊+标准抗结核药物治疗的效果。方法800例老年肺结核患者,根据随机数字表法分为对照组和观察组,每组400例。对照组以标准抗结核药物进行治疗,观察组在对照组基础上辅以利福喷丁胶囊进行治疗。比较两组患者临床疗效、用药前后实验室相关指标[干扰素-γ(IFN-γ)、白细胞介素-6(IL-6)]水平以及用药安全性。结果观察组临床总有效率96.25%高于对照组的80.25%,差异具有统计学意义(P<0.05)。用药6个月后,两组患者IFN-γ均高于用药前,IL-6均低于用药前,且观察组患者IFN-γ(23.05±3.11)ng/L高于对照组的(15.70±2.31)ng/L,IL-6(13.35±2.27)ng/L低于对照组的(58.47±10.25)ng/L,差异均具有统计学意义(P<0.05)。观察组不良反应发生率1.75%(7/400)低于对照组的8.75%(35/400),差异具有统计学意义(P<0.05)。结论利福喷丁胶囊+标准抗结核药物方案治疗老年肺结核既有效又安全可行,临床可积极应用。
Objective To observe the effect of rifapentin capsules combined with standard antituberculosis drugs in the treatment of elderly patients with pulmonary tuberculosis.Methods A total of 800 elderly patients with pulmonary tuberculosis were divided into control group and observation group by random numerical table,with 400 cases in each group.The control group received standard anti-tuberculosis drug therapy,while the observation group received rifapentine capsules on the basis of the control group.The clinical efficacy,laboratory-related indexes[interferon-γ(IFN-γ),interleukin-6(IL-6)]levels before and after treatment,and drug safety were compared between the two groups.Results The total clinical effective rate 96.25%of the observation group was higher than 80.25%of the control group,and the difference was statistically significant(P<0.05).After 6 months of treatment,the IFN-γin both groups was higher than that before treatment in this group,and the IL-6 was lower than that before treatment in this group;the IFN-γ(23.05±3.11)ng/L in observation group was higher than(15.70±2.31)ng/L in control group;the IL-6(13.35±2.27)ng/L in observation group was lower than(58.47±10.25)ng/L in the control group;the differences were all statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 1.75%(7/400),which was lower than 8.75%(35/400)in the control group,and the difference was statistically significant(P<0.05).Conclusion Rifapentin capsules combined with standard anti-tuberculosis drugs is effective,safe and feasible for elderly patients with pulmonary tuberculosis,which can be actively applied in clinical practice.
作者
唐丽华
TANG Li-hua(Tuberculosis Control Institute of Dandong Kuandian Manchu Autonomous County,Dandong 118200,China)
出处
《中国实用医药》
2022年第21期123-125,共3页
China Practical Medicine
关键词
肺结核
标准抗结核药物
利福喷丁胶囊
实验室相关指标
用药安全性
Pulmonary tuberculosis
Standard anti-tuberculosis drugs
Rifapentin capsules
Laboratory related indicators
Drug safety
